<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">endoserg</journal-id><journal-title-group><journal-title xml:lang="ru">Эндокринная хирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Endocrine Surgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2306-3513</issn><issn pub-type="epub">2310-3965</issn><publisher><publisher-name>Типография «Печатных дел Мастер»</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/serg12713</article-id><article-id custom-type="elpub" pub-id-type="custom">endoserg-12713</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Клинический случай</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Clinical Case</subject></subj-group></article-categories><title-group><article-title>Клинический случай индолентного первичного медуллярного рака</article-title><trans-title-group xml:lang="en"><trans-title>Clinical case of indolent primary medullary cancer</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мирошников</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Miroshnikov</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мирошников Сергей Владимирович, д.м.н., eLibrary SPIN: 8588-8707</p><p>460053, Оренбургский район, с. Нежинка, ул. Тенистая, д. 42 </p></bio><bio xml:lang="en"><p>Sergey V. Miroshnikov MD, PhD</p><p>Orenburg district, Nezhinka, 42 Tenistaya street, 460053Orenburg</p></bio><email xlink:type="simple">drmiroshnikov@rambler.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9172-3081</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Демин</surname><given-names>Д. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Demin</surname><given-names>D. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Демин Дмитрий Борисович, д.м.н., профессор, eLibrary SPIN: 3461-9642</p></bio><bio xml:lang="en"><p>Dmitriy B. Demin, MD, PhD, Professor</p></bio><email xlink:type="simple">demindb@yandex.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Беляева</surname><given-names>А. И.</given-names></name><name name-style="western" xml:lang="en"><surname>Belyaeva</surname><given-names>A. I.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Беляева Александра Игоревна, клинический ординатор кафедры хирургии ФГБОУ ВО ОрГМУ, eLibrary SPIN:1518-7777</p></bio><bio xml:lang="en"><p>Alexandra I. Belyaeva, clinical resident of the Department of Surgery OrGMU]</p></bio><email xlink:type="simple">sasha1115@inbox.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБОУ ВО «Оренбургский государственный медицинский университет»; ГАУЗ «Оренбургская областная клиническая больница № 2»<country>Россия</country></aff><aff xml:lang="en">Orenburg State Medical University; Orenburg Regional Clinical Hospital № 2<country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru">ФГБОУ ВО «Оренбургский государственный медицинский университет»<country>Россия</country></aff><aff xml:lang="en">Orenburg State Medical University<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2021</year></pub-date><pub-date pub-type="epub"><day>28</day><month>02</month><year>2022</year></pub-date><volume>15</volume><issue>2</issue><fpage>22</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Мирошников С.В., Демин Д.Б., Беляева А.И., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Мирошников С.В., Демин Д.Б., Беляева А.И.</copyright-holder><copyright-holder xml:lang="en">Miroshnikov S.V., Demin D.B., Belyaeva A.I.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.surg-endojournals.ru/jour/article/view/12713">https://www.surg-endojournals.ru/jour/article/view/12713</self-uri><abstract><p>Медуллярный рак щитовидной железы (МРЩЖ) имеет высокий злокачественный потенциал в преобладающем большинстве случаев, однако у некоторых больных МРЩЖ характеризуется вялым, неагрессивным течением, когда пациенты с наличием доказанной медуллярной карциномы или отдаленными метастазами и/или рецидивом могут жить без прогрессирования достаточно продолжительное время. Такое течение злокачественной опухоли называется индолентным. В статье приведен клинический случай диагностики и лечения индолентного первичного МРЩЖ у пациентки с длительностью заболевания 11 лет, показаны некоторые особенности динамики уровня базального кальцитонина и раково-эмбрионального антигена, ультразвуковые характеристики и данные тонкоигольной пункционной биопсии опухоли. Феномен индолентного течения МРЩЖ, характеризующегося, как правило, высоким злокачественным потенциалом, вероятно, обусловлен биологическими особенностями опухоли и требует дальнейших исследований.</p></abstract><trans-abstract xml:lang="en"><p>Medullary thyroid cancer (MRSH) has a high malignant potential in the vast majority of cases, but in some patients with MRSH is characterized by a sluggish, non-aggressive course, when patients with the presence of proven medullary carcinoma or distant metastases and / or relapse, can live without progression for a sufficiently long time. Such a course of a malignant tumor is called indolent. The article presents a clinical case of diagnosis and treatment of indolent primary MRSH in a patient with a duration of the disease of 11 years. Shows some features of the dynamics of the level of basal calcitonin and cancer-embryonic antigen (CEA), ultrasound characteristics and data of fine-needle puncture biopsy of the tumor. The phenomenon of indolent course of MRSH characterized, as a rule, by a high malignant potential, is probably due to the biological characteristics of the tumor and requires further research.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>индолентный медуллярный рак щитовидной железы</kwd><kwd>кальцитонин</kwd><kwd>раково-эмбриональный антиген</kwd></kwd-group><kwd-group xml:lang="en"><kwd>indolent medullary thyroid cancer</kwd><kwd>calcitonin</kwd><kwd>cancer-embryonic antigen</kwd></kwd-group><funding-group xml:lang="ru"><funding-statement>Оренбургский государственный медицинский университет, г. Оренбург, Россия;	Оренбургская областная клиническая больница № 2, г. Оренбург, Россия</funding-statement></funding-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Газизова Д., Бельцевич Д. Диагностика медуллярного рака щитовидной железы // Врач. — 2013. — №11. — С. 8-9.</mixed-citation><mixed-citation xml:lang="en">Gazizova D, Beltsevich D. Diagnostics of medullary thyroid cancer. Vrach. 2013;11:8-9. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Газизова Д.О., Бельцевич Д.Г., Тюльпаков А.Н., и др. Прогностические критерии клинического течения и диагностика медуллярного рака щитовидной железы // Эндокринная хирургия. — 2013. — №4. — С. 4-13.</mixed-citation><mixed-citation xml:lang="en">Gazizova DO, Beltsevich DG, Tiulpakov AN, et al. Diagnosis of medullary thyroid cancer and prognostic factors of disease aggressiveness. Endocrine Surgery. 2013;4:4-13. (In Russ.). doi: https://doi.org/10.14341/serg201344-13</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Пинский С.Б., Белобородов В.А., Дворниченко В.В., Батороев Ю.К. Наследственный медуллярный рак щитовидной железы // Поволжский Онкологический вестник. — 2019 — Т. 10. — №3. —С. 33-39. doi: https://doi.org/10.1038/nrendo.2012.38</mixed-citation><mixed-citation xml:lang="en">Pinsky SB, Beloborodov VA, Dvornichenko VV, Batoroev YuK. Hereditary medullary thyroid cancer. Volga Oncological Bulletin. 2019;10(3):33-39. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Xu L, Wang W-B, Zhao Y-P, et al. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis. J Surg Oncol. 2012;106(2):169-173. doi: https://doi.org/10.1002/jso.23070</mixed-citation><mixed-citation xml:lang="en">Elisei R, Pinchera A. Advances in the follow-up of differentiated or medullary thyroid cancer. Nat Rev Endocrinol. 2012;8(8):466-475. doi: https://doi.org/10.1038/nrendo.2012.38</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Samulski TD, LiVolsi VA, Montone K, Baloch Z. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: An institutional experience. Pathol - Res Pract. 2014;210(3):182-185. doi: https://doi.org/10.1016/j.prp.2013.12.004</mixed-citation><mixed-citation xml:lang="en">Xu L, Wang W-B, Zhao Y-P, et al. Medullary thyroid carcinoma with nodular goiter carries an excellent prognosis. J Surg Oncol. 2012;106(2):169-173. doi: https://doi.org/10.1002/jso.23070</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Censi S, Cavedon E, Watutantrige-Fernando S, et al. Unique Case of a Large Indolent Medullary Thyroid Carcinoma: Time to Reconsider the Medullary Thyroid Adenoma Entity? Eur Thyroid J. 2019;8(2):108-112. doi: https://doi.org/10.1159/000494675</mixed-citation><mixed-citation xml:lang="en">Samulski TD, LiVolsi VA, Montone K, Baloch Z. The variable pathologic presentations of medullary and micro-medullary thyroid carcinoma: An institutional experience. Pathol - Res Pract. 2014;210(3):182-185. doi: https://doi.org/10.1016/j.prp.2013.12.004</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Бохян В.Ю., Павловская А.И., Коломейцева А.А., и др. Индолентное течение адренокортикального рака: клинико-морфологическая характеристика 7 больных // Эндокринная хирургия. — 2016. — №4. — С. 13-19. doi: https://doi.org/10.14341/serg2016413-19</mixed-citation><mixed-citation xml:lang="en">Censi S, Cavedon E, Watutantrige-Fernando S, et al. Unique Case of a Large Indolent Medullary Thyroid Carcinoma: Time to Reconsider the Medullary Thyroid Adenoma Entity? Eur Thyroid J. 2019;8(2):108-112. doi: https://doi.org/10.1159/000494675</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Leroy X, Camparo P, Gnemmi V, et al. Clear cell papillary renal cell carcinoma is an indolent and low-grade neoplasm with overexpression of cyclin-D1. Histopathology. 2014;64(7):1032-1036. doi: https://doi.org/10.1111/his.12359</mixed-citation><mixed-citation xml:lang="en">Bokhian VU, Pavlovskaya AI, Kolomeytseva AA, et al. Indolent form of adrenocortical carcinoma: clinico-morphological features of 7 patients. Endocrine Surgery. 2016;10(4):13-19. (In Russ.). doi: https://doi.org/10.14341/serg2016413-19</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Diolombi ML, Cheng L, Argani P, Epstein JI. Do clear cell papillary renal cell carcinomas have malignant potential? Am. J. Surg. Pathol. 2015;39(12):1621-1634. doi: https://doi.org/10.1097/PAS.0000000000000513.2</mixed-citation><mixed-citation xml:lang="en">Leroy X, Camparo P, Gnemmi V, et al. Clear cell papillary renal cell carcinoma is an indolent and low-grade neoplasm with overexpression of cyclin-D1. Histopathology. 2014;64(7):1032-1036. doi: https://doi.org/10.1111/his.12359</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Семенов А.А., Бузанаков Д.М., Черников Р.А., и др. Предоперационная оценка риска агрессивного течения медуллярной карциномы щитовидной железы // Вопросы онкологии. — 2021. — T. 67. — №1 — С. 97-104. doi: https://doi.org/10.37469/0507-3758-2021-67-1-97-104</mixed-citation><mixed-citation xml:lang="en">Diolombi ML, Cheng L, Argani P, Epstein JI. Do clear cell papillary renal cell carcinomas have malignant potential? Am. J. Surg. Pathol. 2015;39(12):1621-1634. doi: https://doi.org/10.1097/PAS.0000000000000513.2</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid — a clinicopathologic entity. The Journal of Clinical Endocrinology &amp; Metabolism. 1959;19(1):152-161. doi: https://doi.org/10.1210/jcem-19-1-152</mixed-citation><mixed-citation xml:lang="en">Semenov AA, Buzanakov DM, Chernikov RA, et al. Quantitative assessment of preoperative risk factors for aggressive course of medullary thyroid carcinoma. Probl Oncol. 2021;67(1):97-104. (In Russ.). doi: https://doi.org/10.37469/0507-3758-2021-67-1-97-104</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Alexander EK, Cooper D. The Importance, and Important Limitations, of Ultrasound Imaging for Evaluating Thyroid Nodules. JAMA Intern Med. 2013;173(19):1796. doi: https://doi.org/10.1001/jamainternmed.2013.8278</mixed-citation><mixed-citation xml:lang="en">Hazard JB, Hawk WA, Crile G. Medullary (solid) carcinoma of the thyroid — a clinicopathologic entity. The Journal of Clinical Endocrinology &amp; Metabolism. 1959;19(1):152-161. doi: https://doi.org/10.1210/jcem-19-1-152</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Friedrich-Rust M, Meyer G, Dauth N, et al. Interobserver Agreement of Thyroid Imaging Reporting and Data System (TIRADS) and Strain Elastography for the Assessment of Thyroid Nodules. PLoS One. 2013;8(10):e77927. doi: https://doi.org/10.1371/journal.pone.0077927</mixed-citation><mixed-citation xml:lang="en">Alexander EK, Cooper D. The Importance, and Important Limitations, of Ultrasound Imaging for Evaluating Thyroid Nodules. JAMA Intern Med. 2013;173(19):1796. doi: https://doi.org/10.1001/jamainternmed.2013.8278</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450-455. doi: https://doi.org/10.1210/jc.2006-1590</mixed-citation><mixed-citation xml:lang="en">Friedrich-Rust M, Meyer G, Dauth N, et al. Interobserver Agreement of Thyroid Imaging Reporting and Data System (TIRADS) and Strain Elastography for the Assessment of Thyroid Nodules. PLoS One. 2013;8(10):e77927. doi: https://doi.org/10.1371/journal.pone.0077927</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450-455. doi: https://doi.org/10.1210/jc.2006-1590</mixed-citation><mixed-citation xml:lang="en">Costante G, Meringolo D, Durante C, et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab. 2007;92:450-455. doi: https://doi.org/10.1210/jc.2006-1590</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
